Huikang Biotechnology

Xi'an Huikang Bio-Tech (branded as Witkang) is a prominent biotechnology company specializing in the research and high-scale production of active proteins and peptides. Founded in 2001, the company has developed a sophisticated R&D platform that includes a proprietary international peptide library of 175,000 chains and an AI-driven screening system for protein drug discovery. Its core commercial portfolio features recombinant human collagen (Type I and III fusion) and exosome-based products for wound repair and functional skincare. Huikang's therapeutic pipeline includes innovative programs in ophthalmology, infectious diseases, and regenerative medicine, supported by a 68,000-square-meter industrial park. The company maintains extensive global academic collaborations to advance its recombinant gene and protein expression technologies.